18,400,000 shares if the underwriters option to purchase additional shares is exercised in full) at the per share public offering price.
(2)
The underwriting discount for the shares offered to the public was $0.320625 per share.
The estimated offering expenses payable by us, exclusive of the underwriting discounts and commissions, are approximately $800,000. We have agreed to reimburse the underwriters for expense relating to clearance of this offering with the Financial Industry Regulatory Authority (“FINRA”) up to $35,000.
We have engaged Solebury Capital LLC (“Solebury”), an independent financial adviser and a member of FINRA, to provide certain financial consulting services in connection with this offering. The underwriters have agreed to reimburse us for such financial consulting services provided by Solebury in connection with this offering.
We, as well as all of our directors and officers and the selling stockholders (the “Lock-Up Parties”) have agreed that, without the prior written consent of Morgan Stanley & Co. LLC and Goldman Sachs & Co. LLC on behalf of the underwriters, we and they will not, and will not publicly disclose an intention to, during the period ending 60 days after the date of this prospectus supplement (the “Restricted Period”):
•
offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, any shares of our common stock or any securities convertible into or exercisable or exchangeable for common stock (including without limitation, options or warrants to purchase common stock and limited liability company interests in OpCo (together with the common stock, the “Securities”) or such other Securities which may be deemed to be beneficially owned (as such term is used in Rule 13d-3 of the Exchange Act), by us and the Lock-Up Parties, in accordance with the rules and regulations of the SEC and Securities which may be issued upon exercise of a stock option or warrant (any such securities described in this clause, the “Restricted Securities”);
•
enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of Restricted Securities;
•
file any registration statement with the Commission relating to the offering of any Restricted Securities or any securities convertible into or exercisable or exchangeable for Restricted Securities; or
•
whether any such transaction described above is to be settled by delivery of Restricted Securities or such other securities, in cash or otherwise.
In addition, we and each Lock-Up Party have agreed that, without the prior written consent of Morgan Stanley & Co. LLC and Goldman Sachs & Co. LLC on behalf of the underwriters, we or such Lock-Up Party will not, during the Restricted Period, make any demand for, or exercise any right with respect to, the registration of any Restricted Securities or any security convertible into or exercisable or exchangeable for Restricted Securities.
The lock-up restrictions described above do not apply, with respect to us, to:
•
the issuance by us of shares of Class A common stock upon the exercise of an option or a warrant or the conversion of a security outstanding on the date of this prospectus supplement of which the underwriters have been advised in writing;
•
the shares to be sold in this offering;
•
transfers to us pursuant to a net exercise or cashless exercise by the undersigned of outstanding equity awards pursuant to an employee benefit plan, including to satisfy the exercise price or withholding tax or remittance obligations;
•
the issuance by us of shares of Class A common stock upon the vesting or exercise of restricted stock units, options, stock appreciation rights, warrants to purchase shares of Class A common stock or other equity awards pursuant to an employee benefit plan;
•
the grant of awards, shares or interests pursuant to an employee benefit plan;